449 related articles for article (PubMed ID: 23867133)
21. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
[TBL] [Abstract][Full Text] [Related]
22. Anti-HSV1 activity of brown algal polysaccharides and possible relevance to the treatment of Alzheimer's disease.
Wozniak M; Bell T; Dénes Á; Falshaw R; Itzhaki R
Int J Biol Macromol; 2015 Mar; 74():530-40. PubMed ID: 25583021
[TBL] [Abstract][Full Text] [Related]
23. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations.
Biswas S; Field HJ
Antivir Chem Chemother; 2008; 19(1):1-6. PubMed ID: 18610552
[TBL] [Abstract][Full Text] [Related]
24. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation.
Wozniak MA; Itzhaki RF; Shipley SJ; Dobson CB
Neurosci Lett; 2007 Dec; 429(2-3):95-100. PubMed ID: 17980964
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
[TBL] [Abstract][Full Text] [Related]
26. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease.
Baumeister J; Fischer R; Eckenberg P; Henninger K; Ruebsamen-Waigmann H; Kleymann G
Antivir Chem Chemother; 2007; 18(1):35-48. PubMed ID: 17354650
[TBL] [Abstract][Full Text] [Related]
27. Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner.
Huang WY; Su YH; Yao HW; Ling P; Tung YY; Chen SH; Wang X; Chen SH
J Gen Virol; 2010 Mar; 91(Pt 3):591-8. PubMed ID: 19906941
[TBL] [Abstract][Full Text] [Related]
28. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant.
Sukla S; Biswas S; Birkmann A; Lischka P; Ruebsamen-Schaeff H; Zimmermann H; Field HJ
Antiviral Res; 2010 Jul; 87(1):67-73. PubMed ID: 20420855
[TBL] [Abstract][Full Text] [Related]
29. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.
Betz UA; Fischer R; Kleymann G; Hendrix M; Rübsamen-Waigmann H
Antimicrob Agents Chemother; 2002 Jun; 46(6):1766-72. PubMed ID: 12019088
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Katsumata K; Weinberg A; Chono K; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2012 Jul; 56(7):3587-91. PubMed ID: 22526302
[TBL] [Abstract][Full Text] [Related]
31. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
[TBL] [Abstract][Full Text] [Related]
32. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
[TBL] [Abstract][Full Text] [Related]
33. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
J Alzheimers Dis; 2009; 16(2):341-50. PubMed ID: 19221424
[TBL] [Abstract][Full Text] [Related]
34. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir.
Field HJ; Huang ML; Lay EM; Mickleburgh I; Zimmermann H; Birkmann A
Antiviral Res; 2013 Nov; 100(2):297-9. PubMed ID: 24021190
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.
Katsumata K; Chono K; Kato K; Ohtsu Y; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2013 Mar; 57(3):1339-46. PubMed ID: 23274658
[TBL] [Abstract][Full Text] [Related]
36. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
Shiraki K
Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
[TBL] [Abstract][Full Text] [Related]
37. UL52 primase interactions in the herpes simplex virus 1 helicase-primase are affected by antiviral compounds and mutations causing drug resistance.
Muylaert I; Zhao Z; Elias P
J Biol Chem; 2014 Nov; 289(47):32583-92. PubMed ID: 25278021
[TBL] [Abstract][Full Text] [Related]
38. Alzheimer's disease plaques and tangles: cemeteries of a pyrrhic victory of the immune defence network against herpes simplex infection at the expense of complement and inflammation-mediated neuronal destruction.
Carter CJ
Neurochem Int; 2011 Feb; 58(3):301-20. PubMed ID: 21167244
[TBL] [Abstract][Full Text] [Related]
39. Herpes and Alzheimer's Disease: Subversion in the Central Nervous System and How It Might Be Halted.
Itzhaki RF
J Alzheimers Dis; 2016 Oct; 54(4):1273-1281. PubMed ID: 27497484
[TBL] [Abstract][Full Text] [Related]
40. β-Amyloid peptides display protective activity against the human Alzheimer's disease-associated herpes simplex virus-1.
Bourgade K; Garneau H; Giroux G; Le Page AY; Bocti C; Dupuis G; Frost EH; Fülöp T
Biogerontology; 2015 Feb; 16(1):85-98. PubMed ID: 25376108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
